Cipaglucosidase alfa
Cipaglucosidase alfa is listed in the FDA National Drug Code directory with 1 NDC code. Available dosage form: powder, for solution.
Drug Details
- Generic Name
- Cipaglucosidase alfa
- Brand Names
- N/A
- Application Number
- Sponsor
- Wuxi Biologics Co., Ltd.
- NDC Codes
- 1
- Dosage Forms
- POWDER, FOR SOLUTION
- Routes
- N/A
- Active Ingredients
- CIPAGLUCOSIDASE ALFA
Indications and Usage
1 INDICATIONS AND USAGE POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). POMBILITI is a hydrolytic lysosomal glycogen-specific enzyme indicated, in combination with Opfolda, an enzyme stabilizer, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). ( 1 )